SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending sharply lower as fears escalate that Anthropic's Claude AI tool could disrupt its legacy COBOL modernization services, despite community discussions highlighting IBM's established AI integrations and robust fundamentals.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance (PSKY) is trending as its enhanced all-cash bid for Warner Bros. Discovery (WBD), which addresses debt and includes a ticking fee, has prompted WBD's board to reconsider its options and open a negotiation window. The community is actively debating whether PSKY's clearer regulatory path and financial protections make its bid superior to Netflix's offer, which faces heightened antitrust and political scrutiny.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending after unveiling an ambitious 3-year expansion plan, coinciding with strong revenue growth and global approvals for its ANKTIVA cancer treatment. The community is highly bullish, anticipating a significant short squeeze and long-term valuation surge as the company aims to revolutionize oncology.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian is trending due to a significant post-earnings sell-off, despite reporting strong results, driven by pervasive market fears that AI tools like Claude will disrupt and replace traditional SaaS platforms. This has led to widespread panic among investors over substantial losses, though some believe the stock is now deeply oversold and fundamentally undervalued.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Vir Biotechnology is trending due to a global strategic collaboration with Astellas for its prostate cancer T-cell engager, VIR-5500, backed by promising updated Phase 1 data. The community is actively discussing the potential for a significant run, with some anticipating a short squeeze, while others remain cautious, expecting a historical pullback.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors react to its latest earnings report, which highlighted robust IBSRELA revenue growth and a patent extension until 2042, alongside significant investments in future development that led to near-breakeven profitability. This creates a community debate between long-term growth potential and immediate profits, further fueled by insider buying and ongoing acquisition rumors.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

The cybersecurity sector, including CrowdStrike, is trending amid an AI-driven re-evaluation following the release of Anthropic's Claude Code Security tool, fueling a community debate over whether AI disrupts or enhances enterprise security solutions. Investors are divided between concerns of unsustainable valuations and the belief that leading platforms like CrowdStrike's Falcon system are increasingly vital against evolving AI threats.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and decor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is trending after its Q3 earnings miss, lowered full-year outlook, and cautious 2026 guidance, with the community actively debating the impact of softening housing demand and consumer spending, further fueled by the company's explanation citing a "lack of storms" for sales underperformance.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is trending amid a volatile market reaction to its latest earnings report, with community discussion centered on mixed financial results and intensifying legal and regulatory scrutiny over its compounded GLP-1 offerings. Bears point to potential lawsuits and slowing growth as bulls anticipate a short squeeze following the significant price decline.

FedEx Corp. is a holding company, which engages in the provision of transportation, e-commerce, business services, and business solutions. It operates through the following segments: FedEx Express, FedEx Freight, Corporate, Other, and Eliminations. The FedEx Express segment offers transportation and delivery services. The FedEx Freight segment refers to freight transportation services to business and residences. The FedEx Services segment includes sales, marketing, information technology, communications, customer service, technical support, billing and collection services, and certain back-office functions that support the company's operating segments. The Corporate, Other, and Eliminations segment is involved in the corporate headquarters costs for executive officers and certain legal and finance functions, as well as certain other costs and credits not attributed to the firm's core business. The company was founded by Frederick Wallace Smith on June 18, 1971, and is headquartered in Memphis, TN.

Fedex Corp

FedEx is trending due to a strong earnings beat, optimistic guidance, and plans to spin off its freight business, with many in the community viewing it as a robust play in the logistics sector. Separately, the company's lawsuit against the Trump administration for tariff refunds is generating active debate on corporate responsibility and broader market implications.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of pharma giant Eli Lilly &amp; Co (LLY) jumped over 13% on Thursday after the company surpassed Wall Street’s second-quarter estimates and raised its full-year guidance.The firm reported earnings per share (EPS) of $3.92 compared to an estimate of $2.60 while revenue came in at $11.30 billion versus an estimate of $9.92 billion.However, the highlight of the earnings report came in the form of an increase in its full-year guidance by $3 billion to the range of $45.40 billion to $46.60 billion. Management’s upgraded outlook was primarily driven by the strong performance of Mounjaro and Zepbound, as well as the firm’s non-incretin medicines.Eli Lilly also increased its EPS guidance to the range of $15.10 to $15.60 on a reported basis compared to a previous guidance of $13.05 to $13.55. Non-GAAP EPS is expected to come in at $16.10-16.60 compared to prior guidance of $13.50-14.00.Following the upbeat announcement, retail sentiment on Eli Lilly continued to trend in the ‘bullish’ territory (65/100) amid ‘high’ message volumes.<figure class="image"><a href="https://stocktwits.com/symbol/LLY"><img style="aspect-ratio:1882/522;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_08_at_9_19_54_AM_bfa85cd852.png" alt="Eli Lilly sentiment meter as of 8:48 a.m. EST on August 08, 2024" width="1882" height="522"></a><figcaption>Eli Lilly sentiment meter as of 8:48 a.m. EST on August 08, 2024</figcaption></figure>David A. Ricks, Lilly's chair and CEO said Mounjaro, Zepbound and Verzenio led the firm’s strong financial performance during the quarter. "We also recently received approval of Kisunla to help people with Alzheimer's disease, a moment that was decades in the making,” he said.During the second quarter, worldwide Mounjaro revenue stood at $3.09 billion versus $979.70 million in Q2 2023. Mounjaro is an injectable medicine for type-2 diabetes in adults. Zepbound, which launched in the U.S. for the treatment of adult patients with obesity or overweight with weight-related co-morbidities, saw U.S. revenue come in at $1.24 billion.The firm’s pipeline progress included approval of Kisunla in the U.S. for Alzheimer's disease and Jaypirca in Japan for relapsed or refractory mantle cell lymphoma.Some Stocktwits users, including "HighBetaAlgorithms" are bullish on the stock given that obesity has been a widespread problem in the U.S. and a growing concern globally.<stembedurl>https://stocktwits.com/HighBetaAlgorithms/message/582263226</stembedurl>

Eli Lilly reported earnings per share of $3.92 compared to an estimate of $2.60

Eli Lilly Raises Full-Year Guidance By Whopping $3 Billion, Draws Retail Cheer

The major highlight of the pharmaceutical giant’s earnings came in the form of an increase in its full-year guidance by $3 billion to the range of $45.40 billion to $46.60 billion. 

Eli Lilly Raises Full-Year Guidance By Whopping $3 Billion

Equity

The major highlight of the pharmaceutical giant’s earnings came in the form of an increase in its full-year guidance by $3 billion to the range of $45.40 billion to $46.60 billion. The upgraded outlook was primarily driven by the strong performance of Mounjaro and Zepbound, as well as the firm’s non-incretin medicines.

Current Price	$117.10
Prev Close	$113.30
Open	$114.28
Dividend Yield	N/A
50-Day Moving Average	$112.94
Beta	N/A
Avg. Volume	65,733.00
PE Ratio	N/A

52-Week High	$123.80
52-Week Low	$66.00
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

CURE
Direxion Daily Healthcare Bull 3X Shares

Feed

News

Sentiment

Fundamentals

Info

Latest CURE News

CUREDirexion Daily Healthcare Bull 3X Shares